Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Hummingbird Bioscience Pte. Ltd. manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area. There are currently 4 pending office actions. These actions are distributed across 4 distinct examiners and 3 distinct art units, indicating a broad prosecution landscape for the company's biological filings. This variety of assignments suggests that the company's applications cover multiple specialized sub-fields within the biotechnology sector.
The busiest examiner for the portfolio is BELYAVSKYI, MICHAIL A, who is managing 1 busiest examiner pending action. This means that the 4 pending office actions are assigned to different examiners. The presence of 3 distinct art units shows that the company's technology is being reviewed by several different specialized groups. This decentralized approach requires a coordinated strategy to manage the various examiner interactions and ensure consistent outcomes across the different technical classifications within the USPTO.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| Double-patenting + other | 2 (50%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BELYAVSKYI, MICHAIL A | 1 | 63.9% | +28.0% |
| STONEBRAKER, ALYSSA RAE | 1 | 58.9% | +49.4% |
| MERTZ, PREMA MARIA | 1 | 71.8% | +34.6% |
| GODDARD, LAURA B | 1 | 50.8% | +13.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18458997 | HER3 ANTIGEN-BINDING MOLECULES | GODDARD, LAURA B | 27d |
| 18403476 | HER3-BINDING ANTIBODY-DRUG CONJUGATE | STONEBRAKER, ALYSSA RAE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18458997 | HER3 ANTIGEN-BINDING MOLECULES | GODDARD, LAURA B | 27d |
| 18692314 | TREATMENT AND PREVENTION OF CANCER USING VISTA ANTIGEN-BINDING MOLECULES | BELYAVSKYI, MICHAIL A | — |
| 18403476 | HER3-BINDING ANTIBODY-DRUG CONJUGATE | STONEBRAKER, ALYSSA RAE | — |
| 18518192 | VISTA ANTIGEN-BINDING MOLECULES | MERTZ, PREMA MARIA | — |
| Art Unit | Apps |
|---|---|
| 1642 | 2 |
| 1644 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18692314 | TREATMENT AND PREVENTION OF CANCER USING VISTA ANTIGEN-BINDING MOLECULES | BELYAVSKYI, MICHAIL A | 1644 | §102§103§112DP | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18403476 | HER3-BINDING ANTIBODY-DRUG CONJUGATE | STONEBRAKER, ALYSSA RAE | 1642 | §101§102§103§112 | Non-Final OA | — | Pending | Jan 03, 2024 |
| 18518192 | VISTA ANTIGEN-BINDING MOLECULES | MERTZ, PREMA MARIA | 1674 | §102§112DP | Non-Final OA | — | Pending | Nov 22, 2023 |
| 18458997 | HER3 ANTIGEN-BINDING MOLECULES | GODDARD, LAURA B | 1642 | §103§112 | Final Rejection | 27d | Pending | Aug 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHummingbird Bioscience Pte. Ltd. has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Michail A Belyavskyi has the most, with 1 of Hummingbird Bioscience Pte. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
